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Background: Despite adequate trans-urethral resection of the bladder tumour (TURBT), non-muscle-invasive bladder
cancer (NMIBC) is associated with high rates of recurrence and progression. Instillation of Bacillus Calmette-Guérin
(BCG) into the urinary bladder after TURBT (adjuvant intravesical administration) reduces the risk of both recurrence and
progression, and this is therefore the standard of care for high-risk tumours. However, over 30 % of people still recur or
progress despite optimal delivery of BCG. Our meta-analysis suggests that outcomes might be improved further
by using an adjuvant intravesical regimen that includes both mitomycin and BCG. These promising findings
require corroboration in a definitive, large scale, randomised phase III trial using standard techniques for intravesical
administration.
Methods and design: The BCG + MMC trial (ANZUP 1301) is an open-label, randomised, stratified, two-arm
multi-centre phase III trial comparing the efficacy and safety of standard intravesical therapy (BCG alone) against
experimental intravesical therapy (BCG and mitomycin) in the treatment of adults with resected, high-risk NMIBC.
Participants in the control group receive standard treatment with induction (weekly BCG for six weeks) followed
by maintenance (four-weekly BCG for ten months). Participants in the experimental group receive induction (BCG
weeks 1, 2, 4, 5, 7, and 8; mitomycin weeks 3, 6, and 9) followed by four-weekly maintenance (mitomycin weeks
13, 17, 25, 29, 37, and 41; BCG weeks 21, 33, and 45). The trial aims to include 500 participants who will be centrally
randomised to one of the two treatment groups in a 1:1 ratio stratified by T-stage, presence of CIS, and study site.
The primary endpoint is disease-free survival; secondary endpoints are disease activity, time to recurrence, time to
progression, safety, health-related quality of life, overall survival, feasibility, and resource use.
Trial registration: This trial is registered with the Australian New Zealand Clinical Trials Registry
(ACTRN12613000513718).
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Bladder cancer
Bladder cancer is a major global cause of suffering and mor-
tality. Worldwide, it is among the top 10 cancers in terms
of incidence and mortality with an estimated 380,000 cases
and 150,000 deaths in 2008 [1]. Contrary to trends for most
other cancers, five-year survival from bladder cancer has re-
duced internationally over the last 20 to 30 years [2, 3].
Bladder cancers are classified according to their grade
(high or low) and according to their depth of penetration
through the bladder wall [4]. Muscle-invasive bladder
cancer includes all tumours that invade into detrusor
muscle or beyond (T2-4). Non-muscle-invasive bladder
cancer (NMIBC) includes carcinoma-in-situ (CIS), papil-
lary tumours (Ta), and tumours that invade into lamina
propria but not detrusor muscle (T1). Whilst NMIBC is
often treated successfully with transurethral resection of
the bladder tumour (TURBT), it can be associated with
a high risk of recurrence and progression (increase in
grade or stage). These risks can be estimated based on the
presence, or absence, of certain prognostic indicators [5].
In people with high-risk NMIBC (high-grade Ta, or any
grade T1), the five-year risk of recurrence ranges from 46-
78 % and the five-year risk of progression ranges from 6-
45 % depending on further risk stratification [5]. Disease
progression includes the development of muscle-invasive
disease, which is associated with a poorer prognosis [6]
and usually warrants radical treatment with cystectomy
(removal of the urinary bladder) or irradiation. Various
intravesical therapies (instillation of agents into the urinary
bladder) have been used in the treatment of NMIBC in an
attempt to reduce the risk of recurrence and progression.
Intravesical Bacillus Calmette-Guérin (BCG)
Intravesical BCG is thought to work by stimulating an
antigen-mediated immune response against bladder tumour
cells. Meta-analyses have demonstrated that intravesical
BCG after TURBT (adjuvant BCG) significantly reduces
both the risk of recurrence (odds ratio 0.3, 95 % CI 0.21-
0.43 [7]) and progression (odds ratio 0.73, 95 % CI 0.6-0.89
[8]) of NMIBC, as compared with TURBT alone. The re-
duced risk of progression is only evident if the adjuvant
BCG treatment includes both an induction course (usually
weekly for four-to-six weeks) and a subsequent mainten-
ance course (less frequent instillations over the following
months or years) [8]. In view of the significant toxicities
that can occur with intravesical BCG, its use is currently
not recommended for low-risk NMIBC [4, 9]. Despite opti-
mal delivery of adjuvant BCG, long-term failure rates of 30-
40 % are encountered [10].
Intravesical chemotherapy
Instillation of chemotherapeutic drugs into the bladder
after TURBT (adjuvant intravesical chemotherapy) isanother strategy that is employed in the treatment of
NMIBC, and several different agents have been shown
to be effective. For example, adjuvant intravesical mito-
mycin including an initial and maintenance instillations
has been shown to reduce five-year recurrence rates
from 60 % to 37 % (p < 0.001) [11]. A meta-analysis of
EORTC and MRC randomised clinical trials has demon-
strated that adjuvant intravesical chemotherapy is effect-
ive in reducing recurrence (hazard ratio 0.8, 95 % CI
0.72-88), but not progression or overall survival [12].
Combination intravesical treatment (BCG and
chemotherapy)
Our recent meta-analysis of all published randomised
trials examining the addition of intravesical chemother-
apy to BCG suggests that it may well be beneficial in
people with Ta or T1 disease, but not in those with CIS
alone [13]. When the single trial that included partici-
pants with CIS alone was excluded, the addition of
chemotherapy to BCG was found to reduce both recur-
rence (relative risk 0.75; 95 % CI 0.61 - 0.92) and pro-
gression (relative risk 0.45; 95 % CI 0.25-0.81), with no
apparent increase in treatment toxicity [13]. However,
the only individual randomised trial included in this
meta-analysis that demonstrated significant improve-
ments in recurrence and progression with the addition
of chemotherapy to BCG was a randomised phase II trial
reported by Di Stasi and colleagues [14].
The Di Stasi trial, including 212 participants with
resected T1 tumours, followed for a median of
88 months, found that combined treatment with BCG
and mitomycin improved recurrence rates (42 % vs.
58 %, p = 0.001), progression rates (9 % vs. 22 %, p =
0.045), disease-free survival (median of 69 vs. 21 months,
p = 0.001), overall mortality (22 % vs. 32 %, p = 0.045),
and disease-specific mortality (6 % vs. 16 %, p = 0.01)
compared with BCG alone [14]. However, this trial did
not include people with Ta disease, and mitomycin was
administered using ‘electromotive delivery’ (an electric
current passed through the catheter to plates on the skin
of the lower abdominal wall) - a technique that has not
been widely accepted or adopted. Therefore while these
results are encouraging regarding the benefits of com-
bined treatment with intravesical BCG and mitomycin in
high-risk NMIBC, it remains unproven whether combin-
ation treatment is effective in all subgroups, or when
treatment is delivered in a traditional way (without elec-
tromotive delivery).
Pilot study
Our single-centre, non-randomised, pilot study has
established the feasibility of adding mitomycin to BCG
(without electromotive delivery) as adjuvant intravesical
therapy for resected, high-risk NMIBC [15]. This pilot
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12 BCG alone) and assessed number of missed doses,
treatment completion (number having received 75 % or
more of planned doses), and participant-rated urinary
symptoms. Participant-rated urinary symptoms were
assessed using the I-PSS [16] and a cystitis score [17] at
baseline, three months, six months, nine months, and
one year. No induction treatment doses were missed for
either group (0/99 BCG and mitomycin, 0/72 BCG
alone) and 20 % or fewer maintenance doses were
missed for both groups (8/99 BCG and mitomycin 24/
120 BCG alone). Treatment completion exceeded 80 %
for both groups (10/11 BCG and mitomycin, 10/12 BCG
alone). Failure to complete treatment was due to one
participant (BCG and mitomycin) progressing during
maintenance treatment and requiring cystectomy, and
two participants (both BCG alone) declining mainten-
ance treatment. Of additional note, one participant






































Fig. 1 Pilot data on median (a) I-PSS and (b) cystitis scoresinduction and therefore completed scheduled mitomycin
maintenance only. As can be seen in Fig. 1, combined
treatment with BCG and mitomycin did not result in
worse participant-rated urinary symptom scores at any
interval during the first year, when compared to scores
in those undergoing treatment with BCG alone.
Methods and design
Protocol overview
This is an open-label, randomised, stratified, two-arm
multi-centre phase III trial comparing the efficacy and
safety of standard intravesical therapy (BCG alone)
against experimental intravesical therapy (BCG and mi-
tomycin) in the treatment of adults with resected, high-
risk NMIBC. Participants are randomised centrally to
one of the two treatment groups in a 1:1 ratio stratified
by T-stage, presence of CIS, and study site. It is an
open-label trial because of differences in the appearance,








Hayne et al. BMC Cancer  (2015) 15:432 Page 4 of 7trial is conducted by ANZUP in collaboration with
the NHMRC Clinical Trials Centre, The University of
Sydney. It is supported by funding from Cancer
Australia, and is registered with the Australian New
Zealand Clinical Trials Registry. Central ethical approval
has been obtained from the Sydney Local Health District
Ethics Review Committee (RPAH zone, HREC/13/RPAH/
225). The study has also been approved by the Western
Australian South Metropolitan Health Service Human
Research Ethics Committee. Local ethical approval has
been obtained for all participating centres, which cur-
rently includes the following Australian sites: Sydney
Adventist Hospital, Northern Cancer Institute, Concord
Repatriation General Hospital, Monash Medical Centre,
Royal Melbourne Hospital, Austin Health, The Alfred
Hospital, Footscray Hospital, Box Hill Hospital, Frankston
Hospital, and Fiona Stanley Hospital.
Inclusion criteria
1. Males or females with confirmed high-risk NMIBC
(high-grade Ta, or any grade T1) on initial or
re-resection histology (concurrent CIS is allowed)
2. Aged 18 years or older
3. TURBT performed within eight weeks prior to the
date of randomisation with no remaining
macroscopically visible disease post-resection
4. ECOG performance status of two or less [18]
5. Adequate bone marrow, renal, and liver function
6. Study treatment both planned and able to start
within four weeks of randomisation
7. Has completed the health-related quality of life
questionnaires or is unable to complete them
because of literacy, insufficient English, or limited
vision
8. Willing and able to comply with all study
requirements, including treatment, timing and
nature of all required assessments
9. Signed, written informed consent
Exclusion criteria
1. Contraindications or hypersensitivity to
investigational products, BCG and mitomycin
2. Prior treatment with any other intravesical agent
including BCG or mitomycin (apart from single
doses given post-TURBT)
3. Current or past transitional cell carcinoma of the
upper urinary tract
4. Prior muscle-invasive transitional cell carcinoma of
the bladder
5. Bladder dysfunction precluding intravesical therapy
(e.g. severe urinary incontinence, bladder
overactivity, or bladder spasticity)6. Life expectancy less than three months
7. Congenital or acquired immune deficiencies,
whether due to a concurrent disease,
immunosuppressive therapy, or cancer therapy
8. Prior radiotherapy of the pelvis
9. Prior or current treatment with radiotherapy-
response or biological-response modifiers
10. Clinical evidence of existing active tuberculosis
11. History of another malignancy within five years
prior to registration (apart from non-melanomatous
carcinoma of the skin)
12. Serious medical or psychiatric conditions that
might limit the ability of the patient to comply with
the protocol
13. Pregnancy, lactation, or inadequate contraception.
Women must be post-menopausal, infertile, or use
reliable means of contraception. Women of
childbearing potential must have a negative
pregnancy test done within seven days prior to
registration. Men must have been surgically
sterilised or use a (double if required) barrier
method of contraception.Study treatments
The two treatment regimens use the same (or equiva-
lent) doses and schedule of BCG and mitomycin as the
two arms in Di Stasi’s randomised trial, but without
‘electromotive delivery’ of mitomycin [14]. A summary
of standard (Arm A) and experimental (Arm B) treat-
ment regimens can be seen in Fig. 2.Standard treatment group: BCG alone (Arm A)
Standard intravesical therapy with BCG alone consists of
induction (BCG once a week for six weeks) followed by
four-weekly maintenance starting at week 13 (weeks 13,
17, 21, 25, 29, 33, 37, 41, 45, and 49). BCG (either 2–8 x
108 CFU for OncoTICE™, or 81 mg for ImmunoCYST™
and TheraCys™) is reconstituted with sterile water then
diluted in 50 mL of 0.9 % saline. The same brand of
BCG is used for all treatment administered to an indi-
vidual participant throughout the study.Experimental treatment group: BCG and mitomycin (Arm B)
Experimental intravesical therapy with BCG and mito-
mycin consists of induction (BCG once a week for weeks
1, 2, 4, 5, 7, and 8; mitomycin once a week for weeks 3,
6, and 9) followed by four-weekly maintenance starting
at week 13 (mitomycin weeks 13, 17, 25, 29, 37, and 41;
BCG weeks 21, 33, and 45). Mitomycin (40 mg) is
reconstituted and diluted in 40 mL of sterile water; BCG
is dosed, reconstituted, and brand-nominated as per
Arm A.
Fig. 2 Summary of standard (Arm A) and experimental (Arm B) treatment regimens (displays treatment administration in terms of nominal weeks,
and not calendar weeks, and thus accommodates treatment delays)
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Intravesical treatment is administered in a standard way
with the agent being maintained within the bladder for
approximately one to two hours. Participants are
screened for urinary tract infection (UTI) prior to the
commencement of both induction and maintenance
treatment; additional testing is performed during treat-
ment based on clinical suspicion. No treatment is deliv-
ered within seven days of a TURBT or bladder biopsy, or
in the presence of UTI or significant treatment-related
toxicity. Treatment delays of up to four weeks during in-
duction, and twelve weeks during maintenance, are per-
mitted before the remaining induction or maintenance
doses are omitted. Dose reduction is not permitted for mi-
tomycin, however the dose of BCG can be permanently
reduced to a third of the normal dose at the discretion of
the treating clinician. Treatment is discontinued in the
event of unacceptable toxicity, excessive treatment delay,
disease progression, recurrent high-grade T1 tumours, or
persistent high-grade or T1 tumours despite induction
and four maintenance instillations.
Outcomes and measures
The primary outcome is disease-free survival (DFS). Sec-
ondary outcomes are disease activity, time to recurrence,Table 1 Schedule of assessments
Baseline Induction Maintenance
Blood testsa X Week 13
Urine culture X Week 13
Cystoscopyb TURBT After last instillation After 4th, 7th and la
Health-related
quality of life
X Weeks 3,6,9,13 Weeks 25,37,49
Assessmentsc X Prior to each treatment Prior to each treat
aFull blood count, urea and electrolytes, liver function tests
bUnder local anaesthesia (LA) except at end of induction and maintenance when m
cAssessments include those for treatment toxicity, symptoms of UTI, adverse eventstime to progression, overall survival, adverse events
(assessed using NCI CTCAE v4.0), health-related quality
of life (assessed using QLQBLS-24 [19], QLQ-C30 [20],
I-PSS [16]), feasibility (proportion of participants receiv-
ing at least 75 % of planned instillations), and resource
use (inpatient admissions, outpatient appointments, gen-
eral practitioner and emergency department visits). The
schedule of assessments that occur in the absence of
progression is summarised in Table 1.
Biological and translational sub-studies
Participants provide written informed consent for dona-
tion of formalin-fixed paraffin-embedded tumour tissue
that has already been collected, for use in future bio-
logical or translational sub-studies. These studies aim to
identify biomarkers associated with prognosis or re-
sponse to treatment.
Ethical considerations
The protocol gained central ethics approval in June
2013. The study is conducted in accordance with the
Declaration of Helsinki, Note for Guidance on Good
Clinical Practice (CPMP/ICH/135/95 - annotated with
TGA comments), NHMRC National Statement on Ethical
Conduct in Human Research, NHMRC Australian CodeYear 2 to Year 5
st instillation 3 monthly (Year 2); 6 monthly (Years 3 and 4); at 5 years
3 monthly (Year 2); 6 monthly (Years 3 and 4); at 5 years
ment 3 monthly (Year 2); 6 monthly (Years 3 and 4); at 5 years
ust be under general anaesthesia (GA) with biopsies
, resource use and patient status
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able laws and regulations.
Statistical considerations
The planned sample size of 500 participants (250 per
arm), recruited over four years and followed for another
two years, is designed to give 85 % power to detect a
37 % reduction in the hazard for DFS (hazard ratio 0.63,
corresponding to a two-year DFS probability of 70 %
[BCG alone] vs. 80 % [BCG and mitomycin) at the 5 %
level of statistical significance allowing for a non-
compliance rate of 10 %. Under these assumptions, 213
DFS events (progression or death) are expected to be
observed. The anticipated two-year DFS probability for
the control group (BCG alone, 70 %) is based on results
with single-agent BCG with maintenance in previous
randomised trials and meta-analyses [5, 11, 14].
Analysis plan
The primary analysis will be a comparison of treatment
groups on DFS using a log-rank test; Kaplan-Meier
curves will also be used to estimate DFS at two years.
Cox proportional hazards regression and modelling will
be used to estimate a hazard ratio for the treatment ef-
fect on DFS before and after adjusting for covariates.
Similar analysis will be conducted of other time to event
endpoints including time to recurrence, time to progres-
sion, and overall survival. Comparisons on categorical
and continuous outcomes will be undertaken using suit-
able non-parametric and regression models, and will ad-
just for covariates. Formal cost-effectiveness analyses
will be conducted if the main endpoints warrant consid-
eration of a change in practice.
Additionally, three interim analyses will be conducted;
once the first 130 participants complete treatment, and
after a third and two thirds of the required number of
DFS events have occurred. The interim analyses will as-
sess feasibility, adverse events, study performance, and
preliminary DFS data to determine whether the trial
should stop, be modified, or continue unchanged; these
analyses will be reviewed by an Independent Data and
Safety Monitoring Board.
Discussion
This trial aims to determine whether the addition of
intravesical chemotherapy to adjuvant BCG treatment
reduces the risk of recurrence and progression of high-
risk NMIBC, over treatment with BCG alone. Our meta-
analysis suggests that combination treatment may be
more effective [13], however the only individual study to
prove a benefit did not include people with Ta disease
and delivered mitomycin via unconventional ‘electromo-
tive delivery’ [14]. If this trial confirms the benefits of
combination intravesical therapy with BCG andmitomycin, over BCG alone, in all high-risk NMIBC
subgroups when delivered in a standard way then the
implications of this on the treatment of NMIBC world-
wide would be significant. This trial will assess the com-
parative efficacy of these two treatments by collecting
outcome data including DFS, disease activity, time to re-
currence, time to progression, and overall survival. The
widespread adoption of combination treatment with
BCG and mitomycin will also be affected by its tolerabil-
ity and side-effects as compared to treatment with BCG
alone. The comparative tolerability and side-effects of
the two treatments will be assessed in this trial by col-
lecting data on adverse events, health-related quality of
life, feasibility, and resource use.
Additionally, the consent process for this trial invites
participants to consent to use of formalin-fixed, paraffin-
embedded tumour tissue that is collected, for use in bio-
logical or translational sub-studies. These studies may
potentially provide a better understanding of how BCG
and mitomycin work in NMIBC, or identify biomarkers
that are able to better predict success of intravesical
treatment or overall prognosis.
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